EPZM - エピザイム （Epizyme Inc.） エピザイムEPZMのチャート
EPZMの企業情報
| symbol | EPZM |
|---|---|
| 会社名 | Epizyme Inc. （エピザイム） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エピザイム(Epizyme Inc.)は臨床段階のバイオ医薬品会社である。同社はがん患者向けエピジェネティック治療法の発見・開発・商品化する計画を行う。同社は、がん患者向け新規エピジェネティック治療法の発見・開発に従事する。同社はヒストンメチルトランスフェラーゼ（HMT）として知られる各種酵素小分子阻害剤を開発する。同社は他のクロマチン修飾タンパク質（CMP）の小分子阻害剤を開発する。同社のリード製品候補であるタゼメトスタットは、各種がんにおいて役割を果たす酵素であるゼスト相同体2（EZH2）ヒストンメチルトランスフェラーゼ（HMT）のエンハンサーの選択的阻害剤である。同社は再発性または難治性の非ホジキンリンパ腫（NHL）を有する成人第II相試験及び分子標的腫瘍を有する小児の第I相試験でタゼメトスタットを評価する。同社は日本以外のタゼメトスタットに対する世界的開発・商業化権利を有する。 エピザイムは、米国のバイオ医薬品企業。遺伝によるがん患者向けに個別の治療薬の開発、商品化を行う。ヒストンメチルトランスフェラ―ゼとして知られる酵素の阻害剤作成用に独自の製品プラットフォ―ムを開発。遺伝子変異を持つ急性白血病や、遺伝による非ホジキンリンパ腫および固形腫瘍の治療薬の開発を手掛ける。本社はマサチュ―セッツ州ケンブリッジ。 Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them.. |
| 本社所在地 | 400 Technology Square Cambridge MA 02139 USA |
| 代表者氏名 | David M. Mott デビッド・モット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-229-5872 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 131人 |
| url | www.epizyme.com |
| nasdaq_url | https://www.nasdaq.com/symbol/epzm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -139.26100 |
| 終値（lastsale） | 9.23 |
| 時価総額（marketcap） | 641865774.42 |
| 時価総額 | 時価総額（百万ドル） 737.47240 |
| 売上高 | 売上高（百万ドル） 12.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 521.91640 |
| 当期純利益 | 当期純利益（百万ドル） -136.95600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Epizyme Inc revenues increased 20% to $12M. Net loss increased 4% to $63.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 11% to $54.6M (expense) Stock-based Compensation in SGA increase of 38% to $4M (expense) Other income decrease of 50% to $7K (income). |
EPZMのテクニカル分析
EPZMのニュース
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology 2022/08/12 15:35:00 Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the trans
Epizyme: Q2 Earnings Insights 2022/08/09 12:56:57 Benzinga
Epizyme (NASDAQ: EPZM ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Epizyme beat estimated earnings by 41.67%, reporting an EPS of $-0.21 versus an … Full story available on Benzinga.com
Epizyme GAAP EPS of -$0.21, revenue of $27.5M 2022/08/09 12:29:07 Seeking Alpha
Epizyme press release (NASDAQ:EPZM): Q2 GAAP EPS of -$0.21.Revenue of $27.5M (+111.4% Y/Y).
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance 2022/08/05 09:51:32 Seeking Alpha
Ipsen (IPSEY) (IPSEF) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme (EPZM) to Aug. 11, from Aug
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology 2022/08/12 15:35:00 Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the trans
Epizyme: Q2 Earnings Insights 2022/08/09 12:56:57 Benzinga
Epizyme (NASDAQ: EPZM ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Epizyme beat estimated earnings by 41.67%, reporting an EPS of $-0.21 versus an … Full story available on Benzinga.com
Epizyme GAAP EPS of -$0.21, revenue of $27.5M 2022/08/09 12:29:07 Seeking Alpha
Epizyme press release (NASDAQ:EPZM): Q2 GAAP EPS of -$0.21.Revenue of $27.5M (+111.4% Y/Y).
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance 2022/08/05 09:51:32 Seeking Alpha
Ipsen (IPSEY) (IPSEF) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme (EPZM) to Aug. 11, from Aug
Epizyme Q1 2022 Earnings Preview 2022/05/09 16:10:33 Seeking Alpha
Epizyme (EPZM) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open.The consensus EPS Estimate is -$0.35 (+49.3% Y/Y) and the consensus Revenue Estimate…
Epizyme Announces Date of First Quarter 2022 Financial Results 2022/05/03 11:00:00 Business Wire
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer
Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels. 2022/04/19 15:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Monday, April 18, closing at $0.72, -6.03% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7048 and … Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels. Read More »
Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way? 2022/04/18 14:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Thursday, April 14, closing at $0.76, -6.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7352 and … Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way? Read More »